Boehringer Ingelheim and the EFSD call for grant applications in diabetes research
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
List view / Grid view
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
17 January 2013 | By Johnson & Johnson
Veridex LLC announced an agreement with LabCorp Clinical Trials...
17 January 2013 | By Novartis
"The challenges in delivering healthcare in developing countries are considerable..."
17 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb appoints Mike Burgess...
17 January 2013 | By Boehringer Ingelheim
"Diabetes affects more than 371m people..."
17 January 2013 | By Thomson Reuters
Vifor Pharma has entered into an exclusive distribution agreement with CMS...
16 January 2013 | By WHITECOAT Strategies, LLC
Vestiq announces its launch of products...
Lonza, a leader in biological development and BaroFold, Inc., an innovative protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold’s PreEMT™ high pressure refolding technology for use in biological development refolding processes.
16 January 2013 | By prnewswire.co.uk
The European Commission has approved a new PREZISTA® (darunavir) 800mg tablet...
16 January 2013 | By Amgen
Amgen announced top-line results of the Phase 3 Aranesp® RED-HF® Trial...
16 January 2013 | By Daiichi Sankyo
Daiichi Sankyo and Ranbaxy announced their intention to integrate their business operations in Thailand...
16 January 2013 | By Biogen Idec
Biogen Idec and Elan have submitted applications to the U.S. FDA...
16 January 2013 | By Boehringer Ingelheim
The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."
16 January 2013 | By Amgen
Amgen announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore...
15 January 2013 | By AstraZeneca
AstraZeneca unveiled changes to its executive leadership team...